Axion Biosystems

Activities: Analysis

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Analysis

The best cell viability assays to measure adoptive cell therapy potency

When it comes to measuring the cytotoxicity of CAR-T cells, not all cell viability assays are created equal, says Daniel Millard, Applications Director at Axion Biosystems
Analysis

Leveraging bioelectronic assays for cell-based therapy

Cell-based immunotherapies are revolutionising medicine; and, although they are relatively new, they are poised to disrupt the biomedical industry, reports Dr Jim Ross, Chief Technology Officer and cofounder, Axion Biosystems
Subscribe now